The right dose of prednisone for bronchitis depends almost entirely on which kind of bronchitis you have, and for one of the two common types, the honest answer may be “none at all.” For flare-ups of chronic bronchitis linked to COPD, guidelines typically call for around 30 to 40 mg of oral prednisone (or its equivalent, prednisolone) daily for about five days. For ordinary acute bronchitis, the cough-and-cold illness that sends millions of people to the doctor each winter, clinical trials have failed to show that prednisone shortens symptoms or speeds recovery. That gap between what the evidence supports and what actually gets prescribed is one of the most persistent problems in respiratory medicine.
Acute Bronchitis and Chronic Bronchitis Are Different Diseases
The word “bronchitis” gets used loosely, and that causes real confusion when it comes to treatment. Acute bronchitis is a short-lived inflammation of the airways, almost always triggered by a virus. It typically shows up as a nagging cough that lasts one to three weeks, sometimes with mild wheezing or chest tightness. It resolves on its own. Chronic bronchitis, by contrast, is a long-term condition defined by a productive cough lasting at least three months in two consecutive years, and it usually falls under the broader umbrella of chronic obstructive pulmonary disease (COPD). When someone with COPD has a sudden worsening of symptoms, that is an acute exacerbation of COPD, and it is treated very differently from a garden-variety chest cold.
Most people searching for prednisone doses for “bronchitis” have been given a prescription after an urgent care or primary care visit for a cough. In that scenario, the diagnosis is almost always acute bronchitis, and the evidence for using prednisone is weak to nonexistent. If you have been diagnosed with COPD and are dealing with a flare-up, the picture changes considerably.
Why Prednisone Does Not Help Ordinary Acute Bronchitis
The best evidence on this comes from randomized trials that compared oral corticosteroids with placebo in adults with acute lower respiratory tract infections. In one such trial, patients given prednisolone had a median cough duration of three days, exactly the same as the placebo group, with no meaningful difference in symptom severity.
Even when researchers looked specifically at a subgroup of patients who might have had unrecognized asthma, prednisolone still did not shorten cough or reduce symptom scores compared to placebo. The adjusted difference in cough duration amounted to less than a quarter of a day, and the confidence interval was wide enough that it could easily have gone in either direction.1PubMed Central. Oral prednisolone for acute lower respiratory tract infection in clinically unrecognised asthma: an exploratory analysis of the Oral Steroids for Acute Cough (OSAC) randomised controlled trial In plain terms, prednisone did nothing that a sugar pill couldn’t do.
Some clinicians have wondered whether anti-inflammatory drugs in general might help acute bronchitis, given that airway inflammation is part of the picture. But trials of NSAIDs for acute lower respiratory infection have reached similar conclusions: they are no more effective than placebo at reducing cough duration.2Family Practice Recertification. What is the Best Treatment for Acute Bronchitis? The inflammation that comes with a viral chest infection simply does not respond to these drugs the way chronic airway inflammation does.
When Prednisone Does Work: COPD Exacerbations
The story is completely different for people who have an acute exacerbation of chronic obstructive pulmonary disease. In this setting, systemic corticosteroids improve airflow, reduce treatment failure rates, lower the risk of relapse, and can shorten hospital stays.3PubMed Central. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease Every major set of COPD guidelines recommends a short course of oral corticosteroids when someone has a flare-up.
One well-known trial looked at patients discharged from an emergency department after a COPD exacerbation. Those randomized to oral prednisone had a 30-day relapse rate of about 27 percent, compared with 43 percent in the placebo group. Lung function improved roughly twice as much in the prednisone group over 10 days, and breathlessness scores were significantly better.4PubMed. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease A separate outpatient trial confirmed that prednisone accelerated recovery of oxygen levels, airflow, and peak expiratory flow while cutting the treatment failure rate.5PubMed. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation
These are meaningful benefits, not subtle statistical effects. The improvements in lung function and relapse prevention are large enough that withholding steroids from a genuine COPD exacerbation would be considered substandard care.
The Standard Dose and Why Five Days Is Enough
For COPD exacerbations, the typical regimen is 30 to 40 mg of oral prednisone or prednisolone once daily. Older guidelines suggested continuing for 10 to 14 days, but a Cochrane review that pooled data from multiple trials found that a five-day course is likely sufficient. Across the studies, shorter courses of around five days produced outcomes comparable to longer 10-to-14-day courses, including similar relapse rates and symptom control.6PubMed Central. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease Most of the trials in that review used 30 mg of oral prednisolone daily.
The shift toward shorter courses is a practical win. Every additional day of prednisone increases your exposure to side effects without clear additional benefit. If your doctor prescribes five days at 40 mg, that is in line with current evidence. If you are told to take it for two weeks, it might be worth asking whether a shorter course would work, especially if you are being treated as an outpatient for a moderate flare-up rather than being hospitalized for a severe one.
Low-dose oral regimens appear to work as well as high-dose intravenous ones for most people, which means that for many COPD exacerbations, you can take pills at home rather than receiving IV steroids in a hospital.3PubMed Central. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease
Eosinophils and Who Responds Best
Not everyone with bronchitis or COPD gets the same benefit from prednisone, and one of the strongest predictors of a good response is a type of white blood cell called an eosinophil. In chronic bronchitis patients, those whose sputum contained clusters of eosinophils were far more likely to see lung-function improvements on prednisone than those without eosinophils in their airways.7PubMed Central. Response to corticosteroids in chronic bronchitis
More recent research has extended this finding using blood eosinophil counts, which are easier to check than sputum samples. Patients hospitalized for COPD exacerbations who had blood eosinophil levels at or above 2 percent responded better to oral corticosteroids and had shorter hospital stays than those with lower eosinophil counts.8Respiratory Medicine. Blood eosinophil levels as a biomarker in COPD In patients with non-eosinophilic exacerbations, the benefit of steroids shrank considerably.
This matters because it means prednisone is not a one-size-fits-all treatment even within COPD. If your flare-up is driven primarily by bacterial infection with little eosinophilic inflammation, steroids may not help much, and you are still exposed to the side effects. Some clinicians now use blood eosinophil counts to guide whether to prescribe steroids for a COPD exacerbation, though this approach is not yet universal.
Risks of Even Short Courses
People tend to think of a five-day “burst” of prednisone as harmless, but a large population-based study found that even short courses carry measurable risks. Within 30 days of starting oral corticosteroids, rates of sepsis increased by more than fivefold, venous blood clots increased by about threefold, and fracture risk nearly doubled. Those elevated risks persisted even at doses below 20 mg per day.9PubMed Central. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study The absolute risk for any individual course remains low, but the risks are not zero, and they compound for people who take repeated courses.
Cumulative steroid exposure adds up in other ways too. Each additional course of oral corticosteroids per year has been associated with roughly double the odds of developing adrenal insufficiency, a condition where your body’s own cortisol production becomes suppressed and cannot recover quickly when the drug is stopped.10Respiratory Medicine. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use For someone with COPD who has two or three exacerbations a year, this means the lifetime burden of steroid side effects becomes a serious consideration. Other cumulative effects include thinning bones, elevated blood sugar, weight gain, and increased susceptibility to infections.
These risks are precisely why the evidence showing no benefit for acute bronchitis is so important. If prednisone does nothing for a viral cough, even a small risk of fracture or blood clot is too much risk.
Why Doctors Prescribe It Anyway
Despite the lack of evidence for acute bronchitis, prednisone prescriptions for respiratory infections remain common. Before a stewardship program was introduced at one urgent care network, systemic corticosteroids were prescribed at roughly 20 out of every 100 visits for acute respiratory infections.11PubMed Central. Urgent Care Stewardship for Glucocorticoid Overuse in Acute Respiratory Infections That is a striking number for a drug with no proven benefit in this setting.
When clinicians were surveyed about why they prescribed steroids for these infections, the most common reason, cited by about 63 percent, was wanting to reduce inflammation or ease symptoms. Another 27 percent said they prescribed to meet patient expectations or respond to direct patient requests.11PubMed Central. Urgent Care Stewardship for Glucocorticoid Overuse in Acute Respiratory Infections In other words, many prescriptions are driven by the intuition that reducing inflammation should help, even though trials show it does not, and by pressure from patients who feel they need “something stronger” for a bad cough.
Stewardship programs have shown this pattern can be changed. At the same urgent care network, prescribing rates fell from about 20 per 100 visits to roughly 9 per 100 visits after implementing structured stewardship, a reduction of more than half.11PubMed Central. Urgent Care Stewardship for Glucocorticoid Overuse in Acute Respiratory Infections If you are offered prednisone for a straightforward acute bronchitis without wheezing or a known history of asthma or COPD, it is reasonable to ask your doctor whether the prescription is likely to help.
When Tapering Matters
For a standard five-day burst at 30 to 40 mg, most people can stop abruptly without problems. Tapering, where you gradually reduce the dose over days or weeks, becomes important when courses are longer or when you have taken multiple courses in a short time. The concern is that exogenous prednisone suppresses your body’s own cortisol production. If you stop suddenly after your adrenal glands have dialed down their output, you can experience fatigue, muscle pain, joint aches, low blood pressure, and in severe cases, adrenal crisis.12PubMed Central. The Glucocorticoid Taper: A Primer for the Clinicians
As a rough guide, courses lasting less than a week at moderate doses usually do not require a taper. Courses lasting two weeks or more, or any course in someone who has been on steroids multiple times recently, often do. Your doctor should advise you on this, but if they hand you a 14-day prescription and say nothing about tapering, bring it up.
Dexamethasone as an Alternative
Prednisone and prednisolone are the corticosteroids most commonly prescribed for bronchitis-related conditions, but dexamethasone is sometimes used instead, particularly in children and in settings where adherence to a multi-day course is a concern. Dexamethasone has a longer duration of action, meaning fewer doses are needed.
In pediatric asthma exacerbations, which share some features with bronchitis-related wheezing, a two-day course of dexamethasone has been compared with a five-day course of prednisolone. One trial found that dexamethasone produced fewer emergency department stays beyond six hours, a lower admission rate, and significantly less vomiting.13PubMed Central. Comparative effectiveness of oral dexamethasone vs. oral prednisolone for acute exacerbation of asthma: A randomized control trial A separate trial found the two drugs produced similar outcomes at one week, including similar symptom persistence, quality-of-life scores, and return visit rates, with better adherence in the dexamethasone group.14The Journal of Pediatrics. Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations
For adults with COPD exacerbations, dexamethasone is less well-studied, and prednisone remains the default choice. But if you have trouble tolerating prednisone’s taste, experience nausea, or have difficulty completing a five-day course, dexamethasone is worth discussing with your doctor.
What to Do If You Have a Cough and No Diagnosis
If you are sitting in a waiting room with a cough that has lasted a week or two and someone hands you prednisone, consider a few things before filling the prescription. First, has anyone actually listened to your lungs with a stethoscope and considered whether you might have asthma, COPD, or pneumonia rather than simple acute bronchitis? If the diagnosis is genuinely acute bronchitis in a person without underlying lung disease, prednisone is unlikely to help, and supportive care like staying hydrated, using a humidifier, and treating fever if needed is the standard recommendation.
Second, if you do have COPD or asthma, a short course of prednisone at 30 to 40 mg daily for five days is well supported by evidence. Ask about the duration. If you are prescribed more than a week’s worth, find out why, and whether a shorter course would be equivalent.
Third, pay attention to how often you end up on steroids. If you are getting two or three prescriptions a year, the cumulative side-effect burden becomes a real issue, and it is worth a conversation about longer-term management strategies, like inhaled corticosteroids or bronchodilators, that can reduce how often you need oral steroids in the first place.
The Sputum Question Nobody Asks About
One underappreciated finding from older research is that the character of your sputum may predict whether prednisone will help you. In a crossover trial of chronic bronchitis patients, those whose sputum contained eosinophils were far more likely to respond to 30 mg of daily prednisone. Seven out of nine patients with sputum eosinophilia saw meaningful improvement in lung function, while those without eosinophilia largely did not.7PubMed Central. Response to corticosteroids in chronic bronchitis Interestingly, blood eosinophil counts were not as good a predictor as sputum eosinophils in this particular study, though subsequent research using blood counts has found similar patterns in COPD populations.
In practice, almost no one gets a sputum eosinophil analysis before being prescribed prednisone in an outpatient setting. Blood eosinophil counts are more feasible and are increasingly used in specialist settings to guide steroid therapy for COPD. But in urgent care, where most of these prescriptions originate, the prescription is typically written empirically rather than guided by any biomarker. That gap between what the research suggests and what happens in the exam room is part of why so many people receive prednisone who are unlikely to benefit from it.